Furthermore, in addition to fluid biomarkers, both MRI and PET imaging showed hippocampal atrophy and detectable tau signal, respectively, which correlated with changes in clinically translatable imaging and fluid biomarkers, suggesting that this model may be amenable to detecting effects of treatment on these markers in relatively small studies. This evidence concerns the gene MAPT and hippocampal atrophy.